← Back to calculator
Published Phase 2 human RCT
Retatrutide is an investigational triple-agonist peptide studied for obesity in early-phase trials. This page explains what it is, its regulatory status, how it was studied, and safety considerations — it is a reference overview, not a dosing tool.
Retatrutide dosage calculator →
Arithmetic only, not medical advice.
Retatrutide: reference record
| Regulatory status | Investigational; no FDA/UK/EU marketing approval |
|---|---|
| Route | Subcutaneous |
| Dosing frequency | Once weekly |
| Published range | 1–12 mg |
| Evidence basis | Published Phase 2 human RCT |
| Common vial sizes | 10 (common); confirm on COA |
Sources
- New England Journal of Medicine - DOI 10.1056/NEJMoa2301972Basis for the regulatory status, route, frequency and published range in the table above. Source last checked 2026-06-24
What is Retatrutide?
Retatrutide is an investigational triple agonist, a synthetic peptide designed to act at the GIP, GLP-1 and glucagon receptors at once. It has been studied for obesity in early-phase clinical trials and has no marketed product anywhere.
Is Retatrutide FDA-approved?
No. Retatrutide is investigational and holds no FDA, UK or EU marketing approval. Everything published about it comes from clinical trials rather than from a regulator-approved product label, so there is no approved concentration, presentation or labeled use.
How is Retatrutide given?
In the published Phase 2 obesity trial it was given subcutaneously, once weekly, with escalation controlled by the study protocol. There is no approved route or regimen outside a trial setting.
What are the known safety concerns with Retatrutide?
Trial doses are not prescribing guidance. Formulation, purity and phase-3 protocols may differ from anything obtained outside a clinical trial, and long-term safety has not been established through an approval process.
Phase 2 obesity trial tested 1, 4, 8 and 12 mg weekly with study-controlled escalation
Arithmetic only. No approved commercial concentration, label, or self-use titration exists.
Trial doses are not prescribing guidance; formulation and phase-3 protocols may differ.
Supply-chain quality · Finnrick
Avg quality score
7.2
/10
Purity range
98.74
–
99.95
%
Qty divergence
±
48
%
Vendors · samples
214
·
3,135
Common vial sizes
10 (common); confirm on COA
mg
Test window
Dec 2024 - Jun 2026
Related calculators & comparisons
COMPARISONS
Browse all peptides →